Screener
CRISPR Therapeutics CRSP Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | As of / March 31, 2026 | As of / December 31, 2025 |
|---|---|---|
| Accrued tax liabilities | 638 | 1,113 |
| Operating lease liabilities | 18,612 | 18,578 |
| Other current liabilities | 13,113 | 13,113 |
| Total current liabilities | 136,286 | 149,120 |
| Long-term debt | 585,470 | — |
| Operating lease liabilities, net of current portion | 183,560 | 188,168 |
| Other non-current liabilities | 5,948 | 6,142 |
| Total liabilities | 911,264 | 343,430 |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's total current liabilities?
- CRISPR Therapeutics (CRSP) reported total current liabilities of $136.29M in Q1 2026.
- How has CRISPR Therapeutics's total current liabilities changed year-over-year?
- CRISPR Therapeutics's total current liabilities increased by 14.1% year-over-year, from $119.45M to $136.29M.
- What is the long-term trend for CRISPR Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's total current liabilities has grown at a 9.6% compound annual growth rate (CAGR), from $94.26M to $149.12M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about CRISPR Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude